MTDMEDIUM SIGNALFINANCIAL10-K

MTD's stockholders' equity improved significantly from deeply negative territory while the company expanded operations through debt-funded growth.

The dramatic 81% improvement in stockholders' equity from -$127M to -$24M suggests MTD is making meaningful progress toward financial stability, though it remains in negative equity territory. The company appears to be investing in growth with increased assets, receivables, and inventory, but this expansion is primarily debt-financed as total debt increased 14% to $2.1B.

Comparing 2026-02-06 vs 2025-02-07View on EDGAR →
FINANCIAL ANALYSIS

MTD demonstrated mixed financial performance with substantial improvement in stockholders' equity moving closer to positive territory, while total assets grew 14.6% to $3.7B driven by increases in receivables (+13.3%) and inventory (+13.1%) suggesting business expansion. However, this growth was debt-financed with total debt rising 14% to $2.1B and cash declining 27% to $70M, indicating the company is leveraging up to fund operations and growth. The overall picture shows a company in recovery mode with improving equity position but increasing financial leverage and declining liquidity.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+81.4%
-$126.9M-$23.6M

Equity base grew 81.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Cash & Equivalents
Balance Sheet
-27.3%
$96.0M$69.8M

Cash decreased 27.3% — monitor burn rate and upcoming capital needs.

Total Assets
Balance Sheet
+14.6%
$3.2B$3.7B

Asset base grew 14.6% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+14.1%
$1.2B$1.4B

Current assets grew 14.1% — improving short-term liquidity or inventory/receivables build.

Total Debt
Balance Sheet
+14%
$1.8B$2.1B

Debt rose 14% — additional borrowing for investment or operations; monitor coverage ratios.

Accounts Receivable
Balance Sheet
+13.3%
$687.1M$778.2M

Receivables grew 13.3% — monitor days sales outstanding for collection efficiency.

Inventory
Balance Sheet
+13.1%
$342.3M$387.2M

Inventory built 13.1% — monitor whether demand supports this build or if write-downs may follow.

Total Liabilities
Balance Sheet
+11%
$3.4B$3.7B

Liabilities increased 11% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-02-06
PRIOR — 2025-02-07
ADDED
The aggregate market value of the shares of Common Stock held by non-affiliates of the registrant on June 30, 2025 (based on the closing price for the Common Stock on the New York Stock Exchange as of the last business day of the registrant s most recently completed second fiscal quarter, June 30, 2025) was approximately $ 24.2 billion.
Our actual results or performance may be materially different than reflected in forward-looking statements because of various risks and uncertainties.
Please consider the risks and factors that could cause our results to differ materially from what is described in our forward-looking statements, including ongoing developments related to global trade disputes/tariffs, governmental policies, the geopolitical environment, inflation, the conflict in Ukraine and continuing instability in the Middle East.
Our business is geographically diversified, with net sales in 2025 derived 42% from North and South America, 29% from Europe, and 29% from Asia and other countries.
The laboratory instruments and related service business accounted for approximately 56% of our net sales in 2025 and 2024, compared to 55% in 2023.
The industrial instruments and related service business accounted for approximately 39% of our net sales in 2025, 2024 and 2023.
The retail business accounted for approximately 5% of our net sales in 2025 and 2024, compared to 6% in 2023.
Service (representing service contracts, on-demand services, and replacement parts) accounted for approximately 25% of our net sales in 2025, 24% in 2024, and 23% in 2023.
Over the last three years, we have invested $574 million in research and development ($199 million in 2025, $189 million in 2024, and $185 million in 2023), which is approximately 5% of net sales for each year.
Employees Our total global workforce was approximately 18,100, consisting of 16,600 employees and 1,500 temporary personnel, as of December 31, 2025, and includes approximately 6,200 in Europe, 5,200 in North and South America, and 6,700 in Asia and other countries.
REMOVED
The aggregate market value of the shares of Common Stock held by non-affiliates of the registrant on June 28, 2024 (based on the closing price for the Common Stock on the New York Stock Exchange as of the last business day of the registrant s most recently completed second fiscal quarter, June 28, 2024) was approximately $ 29.7 billion.
Our actual results or performance may be materially different than reflected in forward-looking statements because of various risks and uncertainties, including statements about expected revenue growth, inflation, ongoing developments related to Ukraine, and the conflict in the Middle East.
Please consider the risks and factors that could cause our results to differ materially from what is described in our forward-looking statements, including inflation, ongoing developments related to Ukraine, and the conflict in the Middle East.
Our business is geographically diversified, with net sales in 2024 derived 42% from North and South America, 28% from Europe, and 30% from Asia and other countries.
The laboratory instruments and related service business accounted for approximately 56% of our net sales in 2024, 55% in 2023, and 57% in 2022.
The industrial instruments and related service business accounted for approximately 39% of our net sales in 2024 and 2023 and 38% in 2022.
The retail business accounted for approximately 5% of our net sales in 2024, 6% in 2023, and 5% in 2022.
Service (representing service contracts, on-demand services, and replacement parts) accounted for approximately 24% of our net sales in 2024, 23% in 2023, and 20% in 2022.
Over the last three years, we have invested $551 million in research and development ($189 million in 2024, $185 million in 2023, and $177 million in 2022), which is approximately 5% of net sales for each year.
Employees Our total global workforce was approximately 17,300, consisting of 16,000 employees and 1,300 temporary personnel, as of December 31, 2024, and includes approximately 6,200 in Europe, 4,800 in North and South America, and 6,300 in Asia and other countries.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →